Proteomic analysis of B-cell malignancies
- PMID: 20346427
- DOI: 10.1016/j.jprot.2010.03.010
Proteomic analysis of B-cell malignancies
Abstract
The identification of proteins aberrantly expressed in malignant B-cells can potentially be used to develop new diagnostic, prognostic or therapeutic targets. Proteomic studies of B-cell malignancies have made significant progress, but further studies are needed to increase our coverage of the B-cell malignant proteome. To achieve this goal we stress the advantages of using sub-cellular fractionation, protein separation, quantitation and affinity purification techniques to identify hitherto unidentified signalling and regulatory proteins. For example, proteomic analysis of B-cell plasma membranes isolated from patients with mantle cell lymphoma (MCL) identified the voltage-gated proton channel (HVCN1,[1]). This protein has now been characterised as a key modulator of B-cell receptor (BCR) signalling and abrogation of HVCN1 function could have a role in the treatment of B-cell malignancies dependent on maintained BCR signalling [2]. Similarly, proteomic studies on cell lysates from prognostic subtypes of CLL, distinguished by the absence (UM-CLL) or presence (M-CLL) of somatic hypermutation of the immunoglobulin heavy chain locus identified nucleophosmin 1 (NMP1) as a potential prognostic marker [3,4]. Thus, targeted proteomic analysis on selected organelles or sub-cellular compartments can identify novel proteins with unexpected localisation or function in malignant B-cells that could be developed for clinical purposes.
Copyright © 2010 Elsevier B.V. All rights reserved.
Similar articles
-
Proteomic analysis of malignant B-cell derived microparticles reveals CD148 as a potentially useful antigenic biomarker for mantle cell lymphoma diagnosis.J Proteome Res. 2009 Jul;8(7):3346-54. doi: 10.1021/pr801102c. J Proteome Res. 2009. PMID: 19413345
-
Proteomic analysis of chronic lymphocytic leukemia subtypes with mutated or unmutated Ig V(H) genes.Mol Cell Proteomics. 2003 Dec;2(12):1331-41. doi: 10.1074/mcp.M300055-MCP200. Epub 2003 Oct 13. Mol Cell Proteomics. 2003. PMID: 14557598
-
Diagnosis and prognosis of B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL) and mantle cell lymphoma (MCL).J Egypt Natl Canc Inst. 2005 Dec;17(4):279-90. J Egypt Natl Canc Inst. 2005. PMID: 17102815
-
Differential diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma and other indolent lymphomas, including mantle cell lymphoma.J Clin Exp Hematop. 2020 Dec 15;60(4):124-129. doi: 10.3960/jslrt.19041. Epub 2020 Apr 3. J Clin Exp Hematop. 2020. PMID: 32249238 Free PMC article. Review.
-
Molecular pathogenesis of chronic lymphocytic leukemia.Curr Mol Med. 2006 Sep;6(6):665-75. doi: 10.2174/156652406778195008. Curr Mol Med. 2006. PMID: 17022736 Review.
Cited by
-
Inhibitors of B-cell receptor signaling for patients with B-cell malignancies.Cancer J. 2012 Sep-Oct;18(5):404-10. doi: 10.1097/PPO.0b013e31826c5810. Cancer J. 2012. PMID: 23006944 Free PMC article. Review.
-
Loss of TRPV2 Homeostatic Control of Cell Proliferation Drives Tumor Progression.Cells. 2014 Feb 19;3(1):112-28. doi: 10.3390/cells3010112. Cells. 2014. PMID: 24709905 Free PMC article.
-
The intimate and controversial relationship between voltage-gated proton channels and the phagocyte NADPH oxidase.Immunol Rev. 2016 Sep;273(1):194-218. doi: 10.1111/imr.12437. Immunol Rev. 2016. PMID: 27558336 Free PMC article. Review.
-
SILAC-Based Quantitative Proteomic Analysis of Diffuse Large B-Cell Lymphoma Patients.Int J Proteomics. 2015;2015:841769. doi: 10.1155/2015/841769. Epub 2015 Apr 28. Int J Proteomics. 2015. PMID: 26060582 Free PMC article.
-
Quantitative proteomics to characterize specific histone H2A proteolysis in chronic lymphocytic leukemia and the myeloid THP-1 cell line.Int J Mol Sci. 2014 May 27;15(6):9407-21. doi: 10.3390/ijms15069407. Int J Mol Sci. 2014. PMID: 24871368 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources